Spinal Cord Injury (SCI) is a sudden disruption of spinal cord tissue due to trauma, disease, or degeneration. Its effects vary by injury type and location, causing motor, sensory, and autonomic dysfunction that may be temporary or permanent.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Acute (Incident) Cases of SCI
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases of SCI
</li>
<li dir="ltr" aria-level="1">
Gender-specific Diagnosed Prevalent Cases of SCI
</li>
<li dir="ltr" aria-level="1">
Etiology-specific Diagnosed Prevalent Cases of SCI
</li>
<li dir="ltr" aria-level="1">
Etiology-specific Diagnosed Prevalent Cases of Traumatic SCI
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/spinal-cord-injury-epidemiology-forecast">Spinal Cord Injury Epidemiology</a></h2>
<ul>
<li dir="ltr" aria-level="1">
In 2023, the total diagnosed prevalent cases of Spinal Cord Injury (SCI) in the 7MM were approximately 959K.
</li>
<li dir="ltr" aria-level="1">
The U.S. accounted for 32% of these cases, EU4 and the UK for 56%, and Japan for 12%.
</li>
<li dir="ltr" aria-level="1">
In Japan, around 55% of traumatic SCI cases were caused by falls.
</li>
<li dir="ltr" aria-level="1">
In the U.S., 80% of diagnosed SCI cases were male, while 20% were female.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/spinal-cord-injury-market">Spinal Cord Injury Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The SCI market in the 7MM was valued at approximately USD 345 million in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. market was around USD 146 million in 2023, with growth expected due to upcoming therapies.
</li>
<li dir="ltr" aria-level="1">
The EU4 and the UK contributed about USD 152 million (44% of the total 7MM market), led by Germany (~USD 51 million) and France (~USD 40 million).
</li>
<li dir="ltr" aria-level="1">
Japan's SCI market was valued at approximately USD 47 million in 2023 and is expected to expand during the forecast period.
</li>
<li dir="ltr" aria-level="1">
By 2034, KP&ndash;100IT is estimated to generate around USD 28 million in the 7MM.
</li>
</ul>
<h3 dir="ltr">Spinal Cord Injury Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Advancements in regenerative medicine, neuroprotective agents, and cell-based therapies are driving innovation and expanding treatment options.
</li>
<li dir="ltr" aria-level="1">
Growing public and clinical awareness is leading to earlier diagnosis and better management, supporting market growth.
</li>
<li dir="ltr" aria-level="1">
Advances in rehabilitation technologies and assistive devices are enhancing patient outcomes and quality of life.
</li>
</ul>
<h3 dir="ltr">Spinal Cord Injury Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Current therapies focus mainly on symptom management, with no definitive cure, limiting overall market potential.
</li>
<li dir="ltr" aria-level="1">
Advanced therapies and long-term care needs result in significant healthcare expenditure, restricting access in some regions.
</li>
<li dir="ltr" aria-level="1">
Heterogeneity in injury type and severity makes designing and conducting effective clinical trials challenging.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight">Spinal Cord Injury Therapies</a></h3>
<ul>
<li dir="ltr" aria-level="1">
KP-100IT
</li>
<li dir="ltr" aria-level="1">
Neuro-Cells
</li>
<li dir="ltr" aria-level="1">
MT-3921
</li>
<li dir="ltr" aria-level="1">
Elezanumab (ABT-555)
</li>
<li dir="ltr" aria-level="1">
PMZ-1620 (Sovateltide)
</li>
<li dir="ltr" aria-level="1">
NFX88
</li>
<li dir="ltr" aria-level="1">
NVG-291
</li>
<li dir="ltr" aria-level="1">
AXER-204
</li>
<li dir="ltr" aria-level="1">
ExoPTEN
</li>
</ul>
And others.
<h3 dir="ltr">Spinal Cord Injury Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Nipro Corporation
</li>
<li dir="ltr" aria-level="1">
Kringle Pharma
</li>
<li dir="ltr" aria-level="1">
Neuroplast
</li>
<li dir="ltr" aria-level="1">
Mitsubishi Tanabe Pharma America
</li>
<li dir="ltr" aria-level="1">
AbbVie
</li>
<li dir="ltr" aria-level="1">
BioCT
</li>
<li dir="ltr" aria-level="1">
Pharmazz
</li>
<li dir="ltr" aria-level="1">
Neurofix
</li>
<li dir="ltr" aria-level="1">
NervGen Pharma
</li>
<li dir="ltr" aria-level="1">
ReNetX Bio
</li>
<li dir="ltr" aria-level="1">
NurExone
</li>
</ul>
And others.

Spinal Cord Injury Market

Spinal Cord Injury Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.